Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis

20 Aug 2009

Abstract excerpt

BACKGROUND AND AIMS: Infliximab is an effective treatment for ulcerative colitis with over 60% of patients responding to treatment and up to 30% reaching remission. The mechanism of resistance to anti-tumour necrosis factor alpha (anti-TNFalpha) is unknown. This study used colonic mucosal gene expression to provide a predictive response signature for infliximab treatment in ulcerative colitis. METHODS: Two...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Inflammatory Bowel Disease
Share to Oral microbiology and periodontitis research
Share to Rheumatoid Arthritis Research and Therapies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19700435
DOI: 10.1136/gut.2009.178665

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitisPMID 19700435Read ↗

Gene Expression Profiling and Response Signatures Associated With Differential Responses to Infliximab Treatment in Ulcerative ColitisSemantic proximity Read ↗

Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative ColitisSemantic proximity Read ↗

Mucosal gene expression of inflammatory cytokines as biomarkers for predicting treatment response in patients with inflammatory bowel diseaseSemantic proximity Read ↗

Identification of Specific Biomarkers and Pathways in the Treatment Response of Infliximab for Inflammatory Bowel Disease: In-Silico AnalysisSemantic proximity Read ↗

Identification of novel predictor classifiers for inflammatory bowel disease by gene expression profiling.Semantic proximity Read ↗

Linking Gene Expression to Clinical Outcomes in Pediatric Crohn’s Disease Using Machine LearningSemantic proximity Read ↗

Multigene analysis can discriminate between ulcerative colitis, Crohn's disease, and irritable bowel syndrome.Semantic proximity Read ↗

Characterization of intestinal gene expression profiles in Crohnʼs disease by genome-wide microarray analysisSemantic proximity Read ↗

Correlation of Biomarker Expression in Colonic Mucosa with Disease Phenotype in Crohn's Disease and Ulcerative Colitis.Semantic proximity Read ↗

Discovery of intestinal mRNA expression profiles correlated with mucosal healing of ustekinumab patients with Crohn’s disease: bioinformatics analysis and prospective cohort validationSemantic proximity Read ↗

Downregulated Interferon Signalling in T Cells is Associated with Response to Vedolizumab in Inflammatory Bowel DiseaseSemantic proximity Read ↗

Ulcerative colitis immune cell landscapes and differentially expressed gene signatures determine novel regulators and predict clinical response to biologic therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.